Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOTAXIME SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOTAXIME SODIUM.
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFOTAXIME SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-1A and PBP-3, leading to cell lysis and death.
1-2 g IV every 8-12 hours; maximum 12 g/day
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Terminal elimination half-life is 0.9-1.5 hours in adults with normal renal function; prolonged to 2.5-10 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-6 hours.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal (50-60% unchanged), biliary (5-10%), with approximately 20-30% metabolized to desacetylcefotaxime (also renally eliminated). Total renal elimination of parent drug and metabolite accounts for >80%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic